About: Rapid generation of an anthrax immunotherapeutic from goats using a novel non-toxic muramyl dipeptide adjuvant

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Rapid generation of an anthrax immunotherapeutic from goats using a novel non-toxic muramyl dipeptide adjuvant Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Rapid generation of an anthrax immunotherapeutic from goats using a novel non-toxic muramyl dipeptide adjuvant
Creator	Cirino, Nick Gelder, Frank Kelly, Cassandra O'loughlin, Chris Peterson, Johnny Sower, Laurie
Source	Medline; PMC
abstract	BACKGROUND: There is a clear need for vaccines and therapeutics for potential biological weapons of mass destruction and emerging diseases. Anthrax, caused by the bacterium Bacillus anthracis, has been used as both a biological warfare agent and bioterrorist weapon previously. Although antibiotic therapy is effective in the early stages of anthrax infection, it does not have any effect once exposed individuals become symptomatic due to B. anthracis exotoxin accumulation. The bipartite exotoxins are the major contributing factors to the morbidity and mortality observed in acute anthrax infections. METHODS: Using recombinant B. anthracis protective antigen (PA83), covalently coupled to a novel non-toxic muramyl dipeptide (NT-MDP) derivative we hyper-immunized goats three times over the course of 14 weeks. Goats were plasmapheresed and the IgG fraction (not affinity purified) and F(ab')(2 )derivatives were characterized in vitro and in vivo for protection against lethal toxin mediated intoxication. RESULTS: Anti-PA83 IgG conferred 100% protection at 7.5 μg in a cell toxin neutralization assay. Mice exposed to 5 LD(50 )of Bacillus anthracis Ames spores by intranares inoculation demonstrated 60% survival 14 d post-infection when administered a single bolus dose (32 mg/kg body weight) of anti-PA83 IgG at 24 h post spore challenge. Anti-PA83 F(ab')(2 )fragments retained similar neutralization and protection levels both in vitro and in vivo. CONCLUSION: The protection afforded by these GMP-grade caprine immunotherapeutics post-exposure in the pilot murine model suggests they could be used effectively to treat post-exposure, symptomatic human anthrax patients following a bioterrorism event. These results also indicate that recombinant PA83 coupled to NT-MDP is a potent inducer of neutralizing antibodies and suggest it would be a promising vaccine candidate for anthrax. The ease of production, ease of covalent attachment, and immunostimulatory activity of the NT-MDP indicate it would be a superior adjuvant to alum or other traditional adjuvants in vaccine formulations.
has issue date	2007-10-22(xsd:dateTime)
bibo:doi	10.1186/1476-8518-5-11
bibo:pmid	17953756
has license	cc-by
sha1sum (hex)	0e046152bb9c537c62ed4c4616a0b627ccfc992a
schema:url	https://doi.org/10.1186/1476-8518-5-11
resource representing a document's title	Rapid generation of an anthrax immunotherapeutic from goats using a novel non-toxic muramyl dipeptide adjuvant
has PubMed Central identifier	PMC2104530
has PubMed identifier	17953756
schema:publication	J Immune Based Ther Vaccines
resource representing a document's body	covid:0e046152bb9c537c62ed4c4616a0b627ccfc992a#body_text
is schema:about of	named entity 'ADJUVANT' named entity 'BASED' named entity 'USING' named entity 'major' named entity 'vaccines' named entity 'mortality' named entity 'bipartite' named entity 'exposed' named entity 'MURAMYL DIPEPTIDE' named entity 'NOVEL' named entity 'DOES NOT' named entity 'MAJOR' named entity 'ACCUMULATION' named entity 'AGENT' named entity 'EARLY STAGES' named entity 'WEAPONS OF MASS DESTRUCTION' named entity 'ANTIBIOTIC THERAPY' named entity 'BIOLOGICAL WARFARE' named entity 'BACILLUS ANTHRACIS' named entity 'VACCINES' named entity 'CLEAR' named entity 'HAVE' named entity 'BIOLOGICAL WEAPONS' named entity 'NEED FOR' named entity 'THERAPEUTICS' named entity 'BACTERIUM' named entity 'WEAPON' named entity 'SYMPTOMATIC' named entity 'USED' named entity 'EXPOSED' named entity 'BACKGROUND' named entity 'EXOTOXINS' named entity 'POTENTIAL' named entity 'PREVIOUSLY' named entity 'INFECTIONS' named entity 'IMMUNE' named entity 'ACUTE' named entity 'VACCINES' named entity 'CONTRIBUTING' named entity 'DUE TO' named entity 'NON-' named entity 'TOXIC' named entity 'CAUSED BY' named entity 'INDIVIDUALS' named entity 'IS A' named entity 'BIPARTITE' named entity 'EFFECTIVE' named entity 'EFFECT' named entity 'GOATS' named entity 'THERAPIES' named entity 'GENERATION' named entity 'OBSERVED' named entity 'RAPID' named entity 'ANTHRAX' named entity 'JOURNAL ' named entity 'MORBIDITY AND MORTALITY' named entity 'DISEASES' named entity 'EXOTOXIN' named entity 'ANTHRAX' covid:arg/0e046152bb9c537c62ed4c4616a0b627ccfc992a named entity 'infections' named entity 'therapy' named entity 'morbidity' named entity 'exotoxins' named entity 'biological weapons of mass destruction' named entity 'morbidity' named entity 'Anthrax' named entity 'anthrax' named entity 'adjuvant' named entity 'Vaccines' named entity 'IgG' named entity 'anthrax' named entity 'bacilli' named entity 'botulism toxin' named entity 'inoculation' named entity 'protease'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software